Rhenman & Partners Asset Management AB Sells 107,590 Shares of Natera, Inc. (NASDAQ:NTRA)

Rhenman & Partners Asset Management AB trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 46.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 123,410 shares of the medical research company’s stock after selling 107,590 shares during the quarter. Natera makes up approximately 2.0% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 17th largest position. Rhenman & Partners Asset Management AB owned 0.09% of Natera worth $19,536,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in NTRA. Wilmington Savings Fund Society FSB purchased a new stake in Natera in the third quarter worth about $385,000. Everence Capital Management Inc. purchased a new stake in shares of Natera in the 4th quarter worth approximately $573,000. Smartleaf Asset Management LLC increased its position in Natera by 50.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock valued at $104,000 after buying an additional 220 shares in the last quarter. SeaBridge Investment Advisors LLC purchased a new position in Natera during the fourth quarter valued at $2,894,000. Finally, SYM FINANCIAL Corp bought a new stake in Natera in the fourth quarter worth $256,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $133.87 on Friday. The company has a market capitalization of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00. The firm’s 50 day simple moving average is $156.81 and its two-hundred day simple moving average is $151.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. Guggenheim lifted their price target on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Piper Sandler raised their price target on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. The Goldman Sachs Group upped their price objective on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Morgan Stanley boosted their price target on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Finally, Robert W. Baird boosted their target price on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 663 shares of the stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This represents a 0.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.78, for a total value of $563,120.00. Following the completion of the sale, the director now directly owns 9,704 shares in the company, valued at $1,366,129.12. This trade represents a 29.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 325,922 shares of company stock valued at $51,603,664 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.